The weight-loss drug market has become one of the biggest growth opportunities in healthcare, but investors have increasingly worried about falling prices and intensifying competition. Strong prescription growth means little if manufacturers must continually sacrifice profitability to attract patients.
One pharmaceutical giant just delivered 39% revenue growth, dramatically raised its annual forecast, and unveiled clinical results that could extend its leadership for years.
Let’s dive in.
Closed Door Briefing (Sponsored)
The news shows you missiles.
It doesn't show you the plan.
In two closed-door meetings, United States Congressmen gave Dylan Jovine straight answers.
What looks like chaos in Iran is strategy.
Investors who see it early could be in position before everyone else catches on.
Get the full story here
What Just Happened
Eli Lilly (NYSE: LLY) reported third-quarter revenue of $24.4 billion, up 39% year over year and comfortably ahead of Wall Street's approximately $22.6 billion estimate. Adjusted earnings reached $7.48 per share, compared with expectations around $6.61.
Management raised its 2026 revenue forecast to between $91 billion and $92 billion, up from the previous range of $85 billion to $87 billion. That represents a remarkable $5.5 billion increase at the midpoint.
The company also reported stronger operating profitability, with its adjusted performance margin reaching 54.2%.
Shares jumped more than 6% following Thursday's announcement, reflecting renewed confidence that demand for its obesity and diabetes treatments can overcome growing pricing pressure.
But the more interesting development came from the company's next-generation drug pipeline, where new clinical results suggest its current blockbuster treatments might only be the beginning.
Two Blockbuster Drugs Are Driving Extraordinary Growth
Lilly's growth engine centers on Mounjaro and Zepbound, two medications containing the same active ingredient, tirzepatide, but marketed for different indications.
Mounjaro generated $10.7 billion in quarterly revenue, increasing 65% year over year. Zepbound contributed another $5.35 billion, representing 49% growth.
Combined, the two treatments generated approximately $16.1 billion, accounting for roughly two-thirds of Lilly's total revenue.
That concentration is extraordinary for a pharmaceutical company, but it also demonstrates the enormous commercial opportunity in treating obesity and diabetes.
International demand is becoming particularly important. Mounjaro revenue outside the United States increased 93% to $5.7 billion, helped by broader access and expanding treatment adoption.
Meanwhile, the overall U.S. market for obesity-focused incretin prescriptions grew 82% year over year. Lilly medicines accounted for approximately six out of every ten prescriptions.
These figures suggest the market continues expanding rapidly rather than simply shifting customers between competing manufacturers.
Falling Prices Are Not Stopping Revenue Growth
The most important financial development is that demand is growing substantially faster than prices are declining.
Lilly reported a 53% increase in worldwide sales volume during Q3, partially offset by a 15% decline in realized prices.
That distinction matters because investors have worried that pricing competition, insurance negotiations, and government reimbursement programs would eventually undermine the industry's profitability.
Instead, expanding access appears to be bringing significantly more patients into treatment.
A Medicare pilot program launched in July has already attracted more than 500,000 patients, with approximately 70% choosing Lilly medications.
International reimbursement programs are creating similar opportunities, although they frequently require manufacturers to accept lower prices.
The investment case depends on this trade-off continuing to work. Lilly does not need prices to remain permanently elevated if prescription volumes keep expanding fast enough to support revenue and margin growth.
However, the company's latest quarter also included approximately $900 million in favorable revenue benefits, including a $410 million Jardiance milestone payment and adjustments to rebate estimates.
Those benefits should not be mistaken for recurring product growth.
A New Obesity Pill Opens Another Market
Lilly is also expanding beyond injectable treatments.
Its oral weight-loss medication, Foundayo, launched in April and generated $184 million in third-quarter revenue.
That was below Wall Street's roughly $229 million expectation, suggesting the initial commercialization has been more challenging than investors anticipated.
Competition from Novo Nordisk's oral Wegovy treatment is intense, and patients already have several established injectable alternatives.
Nevertheless, Lilly reported that new Foundayo patient starts doubled from the previous quarter. The drug also captured approximately 40% of patients beginning oral obesity treatment during the period.
This distinction is important because oral treatments could reach patients who are reluctant to use injections, potentially expanding the overall market.
Foundayo can also be taken without the food and water restrictions associated with certain competing oral treatments.
Management expects additional regulatory decisions and international expansion to support future adoption, although the launch still needs to demonstrate stronger sales momentum.
The 'January effect' describes a historical tendency for one category of stocks to outperform in early January, often tied to prior tax-loss selling. Which category?
Treasury Reserve Shift (Sponsored)
"I'm a gold person."
With those words, Trump set something big in motion, and it could affect every retirement account in the country.
Last year gold overtook U.S. Treasuries as the largest reserve asset held by world central banks: 27% of reserves against 22%.
Central banks have bought an average of 1,000 tonnes a year for four straight years.
Go here for the details
*If you would like to unsubscribe from receiving offers for Anchor Point Research, please click here. Or write to: 351 Paseo Nuevo, Floor 2, Santa Barbara, CA, US 93101.
The Next-Generation Drug Could Be Even Bigger
Perhaps the most exciting development came on October 28, when Lilly released new Phase 3 clinical results for retatrutide.
The experimental medication targets three hormone receptors involved in appetite, blood sugar regulation, and metabolism.
In a head-to-head trial involving adults with type 2 diabetes, participants receiving the highest retatrutide dose lost an average of 20.9% of their body weight after 80 weeks.
Participants receiving Ozempic's highest approved 2 mg dose lost approximately 9.4%.
Retatrutide also delivered a greater reduction in A1C, a key measure of blood sugar control.
These results suggest Lilly could eventually offer a treatment with substantially greater weight-loss effectiveness than some existing therapies.
However, the comparison was against Ozempic 2 mg, not every competing obesity treatment, and the highlighted results assume participants remained on assigned treatment. Side effects and treatment discontinuations also require careful consideration.
Lilly expects to seek regulatory approval for retatrutide in 2027.
If approved, the drug could provide another major growth opportunity while helping protect Lilly's market position as competition intensifies.
Profitability Is Improving Despite Heavy Investment
Lilly's financial performance demonstrates the advantages of scaling a highly profitable pharmaceutical franchise.
Third-quarter gross margin reached 83.9%, up from 82.9% a year earlier. Stronger manufacturing efficiency and a favorable product mix helped offset lower selling prices.
Research and development spending increased 23% to $4.2 billion, while marketing and administrative expenses rose 14% to $3.1 billion.
Despite these investments, management raised its full-year adjusted performance-margin forecast to 52% to 52.5%, compared with its previous expectation of 49% to 50.5%.
There is one important earnings complication.
Lilly reduced its 2026 adjusted EPS guidance slightly to $35 to $36, reflecting approximately $4.57 per share in acquired research and development charges from recent transactions.
Underlying earnings expectations improved, but acquisition-related expenses more than offset those gains in the revised forecast.
Those investments could create valuable future products, although their returns remain uncertain.
The Valuation Already Reflects Enormous Expectations
With a market capitalization around $1.2 trillion following the earnings announcement, Lilly commands one of the largest valuations in the pharmaceutical industry.
That represents approximately 13 times management's projected 2026 revenue and nearly 40 times its updated adjusted EPS guidance.
Those multiples are demanding, particularly for a company facing pricing pressure and significant development expenses.
Investors are effectively paying for several years of strong growth from Mounjaro, Zepbound, Foundayo, and the next generation of metabolic treatments.
The encouraging news is that Lilly's 39% revenue growth and expanding margins provide meaningful support for a premium valuation.
The concern is that even an excellent business can deliver disappointing shareholder returns when expectations become too aggressive.
Sustained prescription growth and successful new drug launches will be essential to supporting the valuation.
What Could Trip It Up
Pricing pressure remains the most important financial risk. Worldwide realized prices declined 15% during Q3, and further reductions could eventually overwhelm prescription growth.
Competition from Novo Nordisk and emerging obesity treatments could also pressure market share and profitability.
Lilly's heavy dependence on two blockbuster medications creates concentration risk, while newer products such as Foundayo still need to demonstrate their commercial potential.
Retatrutide faces regulatory and clinical risks despite its encouraging trial results. Approval is not guaranteed, and stronger efficacy does not automatically translate into commercial success.
Finally, the stock's premium valuation leaves limited room for disappointing earnings or slower-than-expected growth.
Space AI Grid (Sponsored)
While everyone is talking about the moon and Mars….
This is the $26.5 trillion SpaceX story nobody is telling you.
It’s Elon’s bold new plan to ship AI off Earth… and launch it into the stars.
And according to the man who called Tesla, “the future of Elon’s mission runs through THIS silent partner company.”
Nvidia even has a stake in Elon’s silent partner too.
Click Here Now For The Details.
My Take
Buy on meaningful pullbacks for long-term exposure to the obesity treatment revolution. Lilly continues demonstrating extraordinary demand growth, improving operating efficiency, and a promising next-generation drug pipeline.
The $5.5 billion revenue forecast increase is especially encouraging because it shows the company's expanding patient base is more than compensating for lower selling prices.
The biggest risk is paying too much for exceptional growth. Lilly's dominant market position makes it an attractive long-term business, but the valuation already reflects considerable optimism.
I would avoid chasing the post-earnings rally and look for opportunities during broader healthcare-sector weakness. The most important indicators will be prescription volumes, realized selling prices, Foundayo adoption, and progress toward retatrutide approval.
Action Recap
💊 Looking to buy? Accumulate on meaningful pullbacks rather than chasing the earnings rally.
📈 Already own it? Hold while prescription growth remains strong and the next-generation pipeline advances.
⚠️ Main risk to respect: Falling drug prices and a premium valuation could offset otherwise impressive growth.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
